Literature DB >> 26198180

Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.

S K Hourigan1,2, L A Chen1,3, Z Grigoryan3, G Laroche1, M Weidner1, C L Sears1, M Oliva-Hemker1.   

Abstract

BACKGROUND: Little data are available regarding the effectiveness and associated microbiome changes of faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in children, especially in those with inflammatory bowel disease (IBD) with presumed underlying dysbiosis. AIM: To investigate C. difficile eradication and microbiome changes with FMT in children with and without IBD.
METHODS: Children with a history of recurrent CDI (≥3 recurrences) underwent FMT via colonoscopy. Stool samples were collected pre-FMT and post-FMT at 2-10 weeks, 10-20 weeks and 6 months. The v4 hypervariable region of the 16S rRNA gene was sequenced. C. difficile toxin B gene polymerase chain reaction was performed.
RESULTS: Eight children underwent FMT for CDI; five had IBD. All had resolution of CDI symptoms. All tested had eradication of C. difficile at 10-20 weeks and 6 months post-FMT. Pre-FMT patient samples had significantly decreased bacterial richness compared with donors (P = 0.01), in those with IBD (P = 0.02) and without IBD (P = 0.01). Post-FMT, bacterial diversity in patients increased. Six months post-FMT, there was no significant difference between bacterial diversity of donors and patients without IBD; however, bacterial diversity in those with IBD returned to pre-FMT baseline. Microbiome composition at 6 months in IBD-negative patients more closely approximated donor composition compared to IBD-positive patients.
CONCLUSIONS: FMT gives sustained C. difficile eradication in children with and without IBD. FMT-restored diversity is sustained in children without IBD. In those with IBD, bacterial diversity returns to pre-FMT baseline by 6 months, suggesting IBD host-related mechanisms modify faecal microbiome diversity.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26198180     DOI: 10.1111/apt.13326

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  34 in total

1.  Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis.

Authors:  Raseen Tariq; Maham Hayat; Darrell Pardi; Sahil Khanna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-26       Impact factor: 3.267

2.  Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease.

Authors:  Krista M Newman; Kevin M Rank; Byron P Vaughn; Alexander Khoruts
Journal:  Gut Microbes       Date:  2017-01-19

Review 3.  Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.

Authors:  Ryan Eliott; Pratik Panchal; Shrish Budree; Alex Scheeler; Geraldine Medina; Monica Seng; Wing Fei Wong; Thomas Mitchell; Zain Kassam; Jessica R Allegretti; Majdi Osman
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

4.  Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.

Authors:  Julia L Drewes; Alina Corona; Uriel Sanchez; Yunfan Fan; Suchitra K Hourigan; Melissa Weidner; Sarah D Sidhu; Patricia J Simner; Hao Wang; Winston Timp; Maria Oliva-Hemker; Cynthia L Sears
Journal:  JCI Insight       Date:  2019-10-03

Review 5.  Fecal microbiota transplantation in children: a brief review.

Authors:  Suchitra K Hourigan; Maria Oliva-Hemker
Journal:  Pediatr Res       Date:  2016-03-16       Impact factor: 3.756

Review 6.  [Fecal microbiota transplantation].

Authors:  C Lübbert; B Salzberger; J Mössner
Journal:  Internist (Berl)       Date:  2017-05       Impact factor: 0.743

Review 7.  Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Krishna Rao; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

8.  Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.

Authors:  Fatouma Salem; Nadège Kindt; Julian R Marchesi; Patrick Netter; Anthony Lopez; Tunay Kokten; Silvio Danese; Jean-Yves Jouzeau; Laurent Peyrin-Biroulet; David Moulin
Journal:  United European Gastroenterol J       Date:  2019-08-01       Impact factor: 4.623

9.  Fecal Microbiota Transplantation Commonly Failed in Children With Co-Morbidities.

Authors:  Richard Kellermayer; Qinglong Wu; Dorottya Nagy-Szakal; Karen Queliza; Faith D Ihekweazu; Claire E Bocchini; Abria R Magee; Numan Oezguen; Jennifer K Spinler; Emily B Hollister; Robert J Shulman; James Versalovic; Ruth Ann Luna; Tor C Savidge
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-02-01       Impact factor: 2.839

10.  Fecal transplantation for treatment of inflammatory bowel disease.

Authors:  Aamer Imdad; Maribeth R Nicholson; Emily E Tanner-Smith; Joseph P Zackular; Oscar G Gomez-Duarte; Dawn B Beaulieu; Sari Acra
Journal:  Cochrane Database Syst Rev       Date:  2018-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.